GSK - Dermavant Sciences IPO: Buy If The Market Capitalization Is $200 Million
With very beneficial results obtained for the treatment of psoriasis, Dermavant Sciences (DRMT) is a name to be followed closely after the IPO goes live. Besides, the Phase 3 clinical results are expected in the first half of 2020. So, market participants willing to profit on this name should acquire shares in 2020. With that said, don’t buy shares if the market capitalization goes above $200 million. Note that the amount of debt is significant, and the asset/liability ratio is below one.
Source: Prospectus
Source: Prospectus
Business
Dermavant Sciences Ltd. is a clinical-stage